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Abstract
Background:Humanmilk oligosaccharides (HMOs) and bioactive proteins are beneficial to infant health. Recent evidence
suggests that maternal nutrition may affect the amount of HMOs and proteins in breast milk; however, the effect of
nutrient supplementation on HMOs and bioactive proteins has not yet been well studied.
Objective: We aimed to determine whether lipid-based nutrient supplements (LNSs) affect milk bioactive protein and
HMO concentrations at 6 mo postpartum in women in rural Malawi. These are secondary outcomes of a previously
published randomized controlled trial.
Methods:Women were randomly assigned to consume either an iron and folic acid capsule (IFA) daily from#20 wk gestation
until delivery, followed by placebo daily from delivery to 6mo postpartum, or amultiple micronutrient (MMN) capsule or LNS daily
from #20 wk gestation to 6 mo postpartum. Breast milk concentrations of total HMOs, sialylated HMOs, fucosylated HMOs,
lactoferrin, lactalbumin, lysozymes, antitrypsin, immunoglobulin A, and osteopontin were analyzed at 6 mo postpartum (n = 647).
Between-group differences in concentrations and in proportions of women classified as having low concentrations were tested.
Results: HMO and bioactive protein concentrations did not differ between groups (P > 0.10 for all comparisons). At 6 mo
postpartum, the proportions of women with low HMOs or bioactive proteins were not different between groups except
for osteopontin. A lower proportion of women in the IFA group had low osteopontin compared with the LNS group after
adjusting for covariates (OR: 0.5; 95% CI: 0.3, 0.9; P = 0.016).
Conclusion: The study findings do not support the hypothesis that supplementation with an LNS or MMN capsule during
pregnancy and postpartum would increase HMO or bioactive milk proteins at 6 mo postpartum amongMalawian women.
This trial was registered at clinicaltrials.gov as NCT01239693. J Nutr 2017;147:1867–74.
Keywords: human milk oligosaccharides, bioactive breast milk proteins, lipid-based nutrient supplements, multiple
micronutrient supplements, lactation, postpartum
Introduction
The health benefits of human milk for infants are well
recognized (1). Human milk contains numerous constituents
such as proteins, fats, carbohydrates, water, electrolytes, vita-
mins, minerals, and other organic compounds, all of which
facilitate infant growth and short- and long-term physical
health. Oligosaccharides and bioactive proteins are among the
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organic compounds produced and transported by the mammary
gland.
Human milk oligosaccharides (HMOs) are a diverse group of
glycans that are highly abundant in human milk. HMOs have
been shown to confer an array of benefits to infants by
promoting specific bacterial colonization of the infant gastroin-
testinal tract. HMOs function as prebiotics for beneficial
bacteria and also act as antiadhesive antimicrobials, modulate
immune and intestinal epithelial cell responses, and may even
benefit the mother via retrograde ‘‘leakage’’ into the circulation
(2). Furthermore, oligosaccharides containing sialic acid and/or
fucose confer additional benefits to the infant by preventing
pathogenic adhesion to intestinal epithelial surfaces and possibly
enhancing brain development (3).
Numerous bioactive proteins found in human milk have been
shown to benefit infants by protecting against infection or
improving the acquisition of nutrients from breast milk. Lacto-
ferrin enhances iron absorption and also has bacteriostatic and
bactericidal properties and modulates the infant immune system
(4). Lactalbumin also enhances the absorption of iron and other
minerals such as calcium and zinc. Furthermore, evidence shows
that lactalbumin indirectly exhibits bactericidal and immune-
stimulating activities through intraintestinal enzymatic cleavage
of lactalbumin into bioactive peptides (5, 6). Lysozymes act both
synergistically with lactoferrin and independently to kill Gram-
negative bacteria (4). Moreover, evidence shows that the con-
sumption of lysozymes is associated with increased expression
of anti-inflammatory cytokine TGF-b and inhibits harmful
Firmicutes bacteria (especially Clostridium) while stimulating
beneficial Bacteroidetes (7). Antitrypsin inhibits the proteolytic
enzyme trypsin, thereby aiding the survival of other bioactive
proteins in the infant gastrointestinal tract (8). IgA is present in
substantial amounts throughout lactation. Antigen-specific IgA
prevents the adherence and penetration of bacterial and dietary
antigens capable of provoking inflammation in the intestinal
mucosa (9). In addition, osteopontin enhances immunologic
development in infants (10), intestinal development in newborn
rhesus monkeys (11), and neurologic and cognitive development
in mouse pups (12).
We recently reported that mothers of severely stunted infants
had significantly fewer sialylated HMOs in their milk than mothers
of nonstunted infants within the Malawi cohort enrolled in the
International Lipid-Based Nutrient Supplements (iLiNS) Project
DYAD (Supplementing Maternal and Infant Diet With High-
Energy,Micronutrient Fortified Lipid-BasedNutrient Supplements)
trial (http://www.ilins.org) (13).We also found substantial variation
in HMO content among women enrolled in the study. A limited
number of studies have aimed to elucidate reasons for such
variation inHMOs and bioactive proteins. Davis et al. (14) recently
found seasonal differences in total HMO abundance in The
Gambia, in which milk samples collected in the dry season (when
food is more plentiful) had higher total HMOs than did milk
samples collected during thewet season (when food is scarcer). This
suggests a relation between maternal dietary intake and HMO
production, although other factors could be involved. Some
evidence shows that a high-protein or high-fiber diet may increase
particular milk oligosaccharides in rats (15), and dietary vitamin A
is also positively associated with the concentration of sialic acid in
human milk (16). In addition, b-carotene supplementation and
high-protein and high-calorie diets have been positively associated
with particular bioactive human milk proteins (17–19), whereas
‘‘malnourishment’’ has been associated with low concentrations of
particular milk proteins (20). Taken together, these studies suggest
that maternal diet influences the production of HMOs and
proteins; however, to our knowledge, no study has yet examined
the effect of providing a nutritional supplement that contains
both macro- and micronutrients on HMOs or bioactive milk
proteins.
The iLiNS-DYAD trials in Malawi and Ghana were designed
to determine whether providing lipid-based nutrient supple-
ments (LNSs) to women during pregnancy and the first 6 mo of
lactation and to children from 6 to 18 mo of age improves fetal
and child growth, micronutrient status, and neurobehavioral
development to a greater extent than consuming iron and folic
acid (IFA) during pregnancy only or a multiple micronutrient
(MMN) tablet during pregnancy and the first 6 mo of lactation.
In this study, we examined the effect of LNS and MMN
supplementation compared with IFA during pregnancy and
placebo postpartum on HMO and bioactive milk protein
concentrations, which were secondary outcomes. Given the
often inadequate nutritional status among pregnant and post-
partum women in Malawi and evidence from The Gambia and
elsewhere that nutrition is associated with production of HMOs
and proteins, we hypothesized that consumption of micro- and
macronutrient supplements is associated with higher concentra-
tions of HMOs and proteins.
Methods
The iLiNS-DYAD-Malawi trial was a randomized controlled, outcome
assessor–blinded supplementation trial of mother-child dyads in the
Mangochi District of Malawi (iLiNS-DYAD-Malawi). The study is
described in detail elsewhere (21). Briefly, we enrolled 1391 pregnant
women who came to one of the study clinics for antenatal care who were
>15 y of age and not >20 gestational weeks. Women who had chronic
medical conditions, pregnancy complications at enrollment (e.g., mod-
erate to severe edema, blood hemoglobin concentration <50 g/L, systolic
blood pressure >160 mm Hg, or diastolic blood pressure >100 mm Hg),
previous enrollment in the iLiNS-DYAD trial, or concurrent enrollment
in another clinical trial were excluded. All 1391 women enrolled were
asked to consume supplements until delivery; a subset of 869 women
were asked to continue supplementation until 6 mo postpartum. Of
those who were still breastfeeding at 6 mo, 647 successfully submitted a
breast milk sample.
Women were randomly assigned to 1 of 3 intervention groups in
blocks of 9 by selecting an opaque envelope that contained 1 of 9 letters.
Each intervention group had 3 letters that corresponded to it. Women in
the IFA group were instructed to consume a capsule that contained
60 mg Fe and 400 mg folic acid (Supplemental Table 1) each day from
enrollment until delivery, and they consumed a placebo capsule from
delivery to 6 mo postpartum. Women in the MMN group were
instructed to consume a capsule that contained 20 mg Fe, in addition
to folic acid and 16 additional micronutrients, each day from enrollment
to 6 mo postpartum. The IFA, placebo, and MMN capsules were
identical in appearance and were contained in bottles labeled with a
letter that corresponded to the intervention. Women in the small-
quantity–LNS group were instructed to consume the following each day
from enrollment until 6 mo postpartum: a 20-g dose of an LNS that
contained the same 18 micronutrients as the MMN capsule, 4 additional
minerals, 2.6 g protein, and 10 g fat and also provided 118 kcal of
energy. Fifteen supplement doses were delivered by the study staff every
14 d. The capsules were manufactured by DSM Nutritional Products
South Africa (Pty) Ltd. The LNS was produced and packed by Nutriset
S.A.S. The capsules and LNSs were stored in a dark environment at 20–
40C. A statistician not involved in the iLiNS-DYAD-Malawi trial (JM
Peerson, University of California, Davis) maintained the intervention
code, which was not broken until all laboratory and statistical analyses
of the primary endpoints were performed.
Trained study staff collected sociodemographic information, includ-
ing age and parity, at the enrollment visit. Information about household
assets was collected and used to form a household asset z score (HHAZ),
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which is a proxy for socioeconomic status. The HHAZ includes
information on the home such as the building materials used, sources
of water, type of lighting used, type of cooking fuel used, and sanitary
facilities. At enrollment, trained anthropometrists measured partici-
pants weight and height in triplicate using high-quality scales (SECA
874 flat scale; Seca GmbH & Co.) and stadiometers (Harpenden
stadiometer; Holtain Limited). HIV was analyzed using a whole-blood
antibody rapid test (Alere Determine HIV-1/2; Alere).
Mothers were asked to manually express the full content of one
breast into a sterile plastic cup. Study staff thoroughly mixed the
contents with a spoon and then transferred 10 mL to storage cryovials,
which were stored at 280C until analysis. HMOs were analyzed by a
nano-LC-chip–time-of-flight MS method as described previously (22)
and are reported as normalized ion counts. Lactoferrin, lactalbumin,
lysozymes, antitrypsin, IgA, and osteopontin were analyzed by multiple
reaction monitoring (MRM). MRM is a highly sensitive technique that
has been widely used with proteins (23–26) and small molecule
metabolites (27, 28) for absolute quantitation. MRM is a targeted
quantitation technique and requires the molecular weight of the analyte
and its fragment ions under collision-induced dissociation. In MRM, the
analyte of interest is selected in the first quadrupole, fragmented in the
collision cell, and 2 fragment ions (a quantifier and a qualifier) are
selected and monitored in the third quadrupole for quantitation. For
absolute quantitation of human milk proteins, $2 unique peptides from
each milk protein were selected for monitoring with theMRM technique
(29). Concentrations of lactoferrin, lysozymes, antitrypsin, and IgA were
obtained using calibration curves of known amounts of protein standards.
Osteopontin standards were not available at the time of analysis, so
relative protein amounts are presented as ion counts.
We performed statistical analysis with SAS software (version 9.4; SAS
Institute Inc.) according to an analysis plan that was written and
published before the intervention code was opened (www.ilins.org). We
based the analysis on an intention-to-treat principle. That is, results for
all women enrolled were analyzed according to the group to which they
were assigned regardless of any protocol violations. Data on participants
who were lost to follow-up because of death, travel from the study site,
or refusal to continue with the study were included in the analysis if
available. Outcome variables were inspected for conformance to normal
distribution and were transformed where necessary. Sialylated HMOs,
lactoferrin, lysozymes, and IgA were log transformed before analyses
were performed. No suitable transformation could be achieved for
osteopontin, so a ranked ANCOVA approach was used to test the
differences between intervention groups (30).
P values for differences in characteristics between women who were
included and excluded from the HMO analyses were obtained from a
t test for comparisons of means or a Fishers exact test for comparisons of
proportions (we present these analyses only from women included and
excluded from the analyses of HMOs because the women included in the
HMO analyses were very similar to those included in the protein
analyses). Groupwise differences in outcome variables at 6 mo postpar-
tum were analyzed using ANCOVA for continuous outcomes and
logistic regression for dichotomous outcomes. After we performed a
closed testing procedure to control the type I error rate (31), a hypothesis
on pairwise difference was rejected at the 5% level only if the global null
hypothesis of no difference between any of the 3 groups was also rejected
at the 5% level. Pairwise comparisons were performed with a Tukey-
Kramer adjustment. Both unadjusted and covariate-adjusted testing of
differences between intervention groups was performed. For adjusted
models, covariates that have been shown to be associated with the
outcome variable and were significantly associated with the outcome
variable on bivariate analysis (P < 0.10) were included. Potential
covariates included baseline maternal BMI (in kg/m2), HIV status, parity,
maternal age, HHAZ, and season (at 6 mo postpartum). In addition to
the 3-group analysis, data for the IFA and MMN groups were combined
and compared with the LNS group.
The effects of potential effect modifiers were assessed with an
interaction term in the ANCOVA (for continuous outcomes) or logistic
regression (for bivariate outcomes). To understand the nature of the
effect modification, significant interactions (P < 0.05) were further
examined by estimating the adjusted means at the 10th and 90th
percentiles of the effect modifier. The potential effect modifiers included
the following variables: baseline maternal BMI, HIV status, parity, age,
socioeconomic status, and season (at 6 mo postpartum).
Results
Of the 869 women selected to continue supplementation until
6 mo postpartum, 749 were still enrolled at 6 mo postpartum
(Figure 1) and >99% were still breastfeeding. Breast milk was
successfully collected from 659 women at 6 mo postpartum.
After we excluded mothers of twins (n = 10), HMO data were
FIGURE 1 Schematic representation of recruitment, enrollment,
and follow-up of Malawian women who participated in the Interna-
tional Lipid-Based Nutrient Supplements Project. HMO, human milk
oligosaccharide; IFA, iron and folic acid; LNS, lipid-based nutrient
supplement; MMN, multiple micronutrient.
Effect of LNSs on HMOs and milk proteins 1869
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available from 647 women and protein data were available from
637 women. Samples from 2 participants (1 each in the IFA and
LNS groups) did not meet HMO quality control standards and
samples from 12 participants (3, 4, and 5 in the IFA, MMN, and
LNS groups, respectively) did not meet bioactive protein quality
control standards and were excluded from analysis.
Baseline characteristics of participants included and excluded
from the HMO analyses are shown in Table 1. Included
participants had, on average, lower socioeconomic status
(0.15 SD; P = 0.010) and lower BMI (0.5 points: P = 0.011)
than excluded participants.
At 6 mo postpartum, there were no significant differences in
mean concentrations of total HMOs, sialylated or fucosylated
HMOs, lactoferrin, lactalbumin, lysozymes, antitrypsin, IgA, or
osteopontin between the 3 intervention groups in either the
unadjusted or adjusted models (each P > 0.10) (Table 2). There
were also no differences between groups when the IFA and MMN
groups were combined and comparedwith the LNS group in either
unadjusted or adjusted models (each P > 0.10, data not shown).
There were no significant differences in the proportion of
women with low concentrations of total HMOs, sialylated
HMOs, fucosylated HMOs, lactoferrin, lactalbumin, lyso-
zymes, antitrypsin, or IgA between the 3 intervention groups in
either adjusted or unadjusted models (each P > 0.10) (Table 3)
or when the combined IFA and MMN group was compared
with the LNS group (data not shown). There was a trend
toward reduced odds of women in the IFA group having low
osteopontin compared with the LNS group in unadjusted
models (P = 0.095 for the overall model; P = 0.083 for IFA
compared with LNS). The difference became significant after
adjusting for covariates (P = 0.021 for the overall model; OR:
0.5; 95% CI: 0.3, 0.9; P = 0.016 for IFA compared with LNS).
When the combined IFA and MMN group was compared with
the LNS group, the proportion of women with low osteopontin
did not differ in unadjusted models (P = 0.106); after adjusting
for covariates, women in the IFA andMMN group had reduced
odds of having low osteopontin (OR: 0.6; 95% CI: 0.4–0.96;
P = 0.030; data not shown).
Interactions of treatment group with either maternal HIV
status or the season during which the breast milk sample was
collected were not significant for any of the outcomes
(each P > 0.05). The association between the intervention group
and mean IgAwas modified by maternal BMI (P = 0.008) (Table
4). Specifically, the MMN group had higher IgA than the IFA
group among women with a low BMI, but there were no
group differences among those with a higher BMI. For low
fucosylated HMOs, there was a significant interaction between
the intervention group and HHAZ (P = 0.048), but the analyses
at different concentrations of HHAZ did not show consistent
results. The proportion of women with low antitrypsin was
modified by parity (P = 0.012) and maternal age (P = 0.046).
There was a greater proportion of women with low antitrypsin
in the LNS group than the IFA group among primiparous
women and young women, but there were no between-group
differences for multiparous or older women.
Discussion
To our knowledge, this is the first study to examine the effect
of MMN supplements or LNSs on breast milk oligosaccha-
rides (total, fucosylated, and sialylated HMOs) and bioactive
proteins (lactoferrin, lactalbumin, lysozymes, antitrypsin, IgA,
and osteopontin).We found that consumption ofMMNs as either
an MMN capsule or within an LNS during pregnancy and for
6 mo postpartum had no impact on mean breast milk concen-
trations of oligosaccharides or bioactive proteins at 6 mo postpar-
tum. However, women in the control group (IFA consumed
during pregnancy, followed by a placebo capsule from delivery
to 6mo postpartum)were less likely to have lowmilk osteopontin
concentrations at 6 mo postpartum.
To date, very few studies have examined the effect of
consumption of particular nutrients on HMOs. Rat dams fed
either a high-protein or high-fiber diet, compared with a control
diet, had higher concentrations of 2 particular milk oligosac-
charides (15): hexose plus 1 N-Acetylglucosamine, which is
neither sialylated nor fucosylated, yet appears to be important
for the development of the intestinal microbiota and is strongly
related to particular microbes found in breast-fed infants; and 2
hexose plus sialic acid, a sialylated HMO used by Bacteroides
infantis that may help prevent the adherence of pathogens to the
epithelial surface. However, in this study, the relative increase in
protein intake among women in the LNS group than in the IFA
or MMN groups was much lower than the relative increase in
the protein and fiber intake of the group of rats that consumed
the high-protein or high-fiber rat chow and was likely not large
enough to affect HMO content. A separate cross-sectional
study of Chinese women showed a positive association between
dietary vitamin A intake reported via a 72-h food recall and
sialic acid in breast milk, and a higher reported vitamin A intake
was reported among women with high concentrations of
sialylated HMOs (16). Our intervention trial did not show
differences in sialylated HMOs among women who were
supplemented with 800 mg retinol equivalents/d (in LNSs or
MMNs) compared with IFA.
There is a bit more evidence regarding associations of dietary
components with specific human milk proteins. Pregnant and
lactating mice supplemented with 50 mg of b-carotene/kg body
weight had increased milk secretion of IgA compared with mice
fed a control diet (17). However, none of the supplements
consumed by women in our study contained b-carotene. In
addition, the breast milk IgA concentration was higher in
Guatemalan women randomly assigned to receive a high-energy
(500 kcal/d) or a low-energy (140 kcal/d) supplement during
lactation (18). In other studies,milk lactoferrin and a-lactalbumin
concentrations tended to be higher when women (n = 3)
received a high-protein diet (20% of kcal from protein) than a
low-protein diet (8% of kcal from protein) (19), and milk
lysozyme and IgA concentrations were lower among women
considered to be malnourished (n = 10; BMI, serum total protein,
TABLE 1 Baseline characteristics of Malawian women included
and excluded from intervention group comparisons of human milk
oligosaccharides at 6 mo postpartum1
Characteristic
Included
(n = 647)
Excluded
(n = 744) P value2
Maternal age, y 25.1 6 6.0 24.7 6 6.2 0.187
Proxy for socioeconomic status 20.07 6 1.05 0.08 6 0.96 0.010
Primiparous women 136 (21.1) 166 (22.7) 0.473
BMI, kg/m2 21.9 6 2.7 22.4 6 3.0 0.011
Women with a low BMI (,18.5) 36 (5.6) 38 (5.2) 0.811
Women with a positive HIV test result 79 (12.3) 101 (14.9) 0.173
1 Values are means 6 SDs or n (%).
2 P values are expressed for the difference in characteristics between those included
and excluded from analyses, as determined by the t test for continuous variables and
by Fishers exact test for comparisons of proportions.
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and albumin below established cutoffs) than in ‘‘well-nourished’’
women (n = 50) (20). The fact that we found no differences
between intervention groups in these bioactive proteins may be
attributable to the relatively low energy and protein content of the
LNS compared with supplements used in other studies.
The lower odds of low osteopontin among women in the IFA
group than in the LNS group may be a spurious association;
however, it could be related to the higher dose of iron during
pregnancy provided to women in the IFA group (60 mg/d) than
to those in the LNS (or MMN) group (20 mg/d). In Wistar rats,
serum osteopontin was increased among those fed a 5% iron
lactate diet for 4 wk postpartum compared with those fed a
control diet (32). Although the authors did not propose a
mechanism by which iron increased osteopontin, they reported
higher oxidative stress within the iron group, and osteopontin
was shown in a separate study to be elevated during oxidative
stress (33). Milk osteopontin was not measured in the study
above; however, plasma and breast milk osteopontin were found
to be significantly correlated among 20 postpartumwomen (34).
The influence of iron consumed during pregnancy or postpartum on
breastmilk osteopontin concentrationwarrants further investigation,
because osteopontin is shown to be associated with an improved
cytokine profile and decreased infections in infants (35) and
improved neurologic and cognitive development in mouse pups (12).
We found a few statistically significant interactions for some
of the milk outcomes between certain maternal characteristics
and the intervention group. Among women with a low BMI, the
mean breast milk IgA concentration was higher among those
who consumed IFA than MMN or LNS, but no such differences
were observed among women with a higher BMI. Atlhough this
may be a spurious finding, it is possible that women with a low
BMImay not consume adequate iron in their diet compared with
TABLE 3 Proportion of participants with HMOs and bioactive proteins below specified cutoffs among Malawian women who
consumed different formulations of micronutrients during pregnancy and until 6 mo postpartum1
Variable IFA MMN LNS P value2
Comparison
IFA and MMN IFA and LNS MMN and LNS
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Total HMOs ,0.55 57 (25.9) 54 (24.2) 49 (23.8) 0.872 1.1 (0.7, 1.8) 0.932 1.1 (0.7, 1.9) 0.868 1.0 (0.6, 1.8) 0.987
Sialylated HMOs ,0.060 55 (25.0) 58 (26.2) 50 (24.3) 0.893 0.9 (0.6, 1.6) 0.952 1.0 (0.6, 1.8) 0.983 1.1 (0.7, 1.9) 0.886
Fucosylated HMOs ,0.33 57 (25.9) 53 (24.0) 51 (24.8) 0.895 1.1 (0.7, 1.9) 0.887 1.1 (0.6, 1.8) 0.960 1.0 (0.6, 1.6) 0.981
Lactoferrin ,0.74 53 (24.3) 54 (24.9) 51 (25.3) 0.975 1.0 (0.6, 1.6) 0.989 1.0 (0.6, 1.6) 0.973 1.0 (0.6, 1.7) 0.996
Lactalbumin ,1.2 55 (25.2) 56 (25.8) 49 (24.3) 0.934 1.0 (0.6, 1.6) 0.990 1.1 (0.6, 1.8) 0.971 1.1 (0.6, 1.9) 0.929
Lysozyme ,0.030 48 (22.0) 56 (25.8) 56 (27.7) 0.389 0.8 (0.5, 1.4) 0.624 0.7 (0.4, 1.3) 0.368 0.9 (0.5, 1.5) 0.898
Antitrypsin ,0.026 49 (22.5) 51 (23.5) 60 (29.7) 0.188 0.9 (0.6, 1.6) 0.965 0.7 (0.4, 1.2) 0.212 0.7 (0.4, 1.2) 0.324
IgA ,0.25 53 (24.3) 53 (24.4) 51 (25.3) 0.971 1.0 (0.6, 1.7) .0.999 1.0 (0.6, 1.6) 0.973 1.0 (0.6, 1.6) 0.979
Osteopontin ,18,200 44 (20.2) 57 (26.3) 59 (29.2) 0.095 0.7 (0.4, 1.2) 0.292 0.6 (0.4, 1.1) 0.0833 0.9 (0.5, 1.4) 0.780
1 Values are n (%) unless otherwise indicated. Normalized ion counts are given for total, sialylated, and fucosylated HMOs and ion counts are given for osteopontin. All other
values are given in grams per liter. HMO, human milk oligosaccharide; IFA, iron and folic acid; LNS, lipid-based nutrient supplement; MMN, multiple micronutrient.
2 Unadjusted global P values are presented for differences between 3 intervention groups as determined by logistic regression. After adjusting for covariates, no comparisons
became statistically significant, other than osteopontin.
3 After adjusting for covariates, this difference became significant (P = 0.021 for the overall model; P = 0.016 for IFA compared with LNS).
TABLE 4 Significant interactions with the effect of intervention on mean breast milk IgA and proportions with low fucosylated HMOs
or antitrypsin at 6 mo postpartum among Malawian women who consumed different formulations of micronutrient supplements during
pregnancy and until 6 mo postpartum, by baseline level of the effect modifiers1
Outcome Level of effect modifier IFA MMN LNS P-interaction2 P value3
IgA BMI 0.008
10th percentile 0.33 (0.30, 0.36)a 0.27 (0.25, 0.30)b 0.29 (0.26, 0.32)a,b 0.003
90th percentile 0.30 (0.27, 0.33) 0.33 (0.30, 0.37) 0.34 (0.31, 0.37) 0.121
Low fucosylated HMO HHAZ 0.048
10th percentile 0.26 (0.20, 0.34) 0.17 (0.12, 0.24) 0.23 (0.17, 0.31) 0.174
90th percentile 0.26 (0.17, 0.37) 0.37 (0.27, 0.48) 0.27 (0.17, 0.38) 0.270
Low antitrypsin Parity 0.012
Primiparous 0.10 (0.06, 0.17)a 0.16 (0.10, 0.24)a,b 0.29 (0.20, 0.41)b 0.003
Multiparous 0.44 (0.31, 0.59) 0.32 (0.21, 0.45) 0.29 (0.19, 0.42) 0.234
Maternal age 0.046
10th percentile 0.15 (0.09, 0.26)a 0.24 (0.15, 0.35)a,b 0.35 (0.25, 0.48)b 0.015
90th percentile 0.28 (0.18, 0.41) 0.20 (0.12, 0.32) 0.22 (0.13, 0.34) 0.459
1 Values are estimated means (95% CIs) at the 10th and 90th percentiles of the effect modifier for continuous outcome variables as determined by ANCOVA after adjusting for
covariates unless otherwise indicate. The estimated probability of low outcomes (95% CIs) at the 10th and 90th percentiles of the effect modifier for binary outcomes was
determined by logistic regression after adjusting for covariates. IgA was log transformed before analyses were performed. IgA was adjusted for HHAZ, maternal HIV status,
maternal BMI (in kg/m2), and season. Low fucosylated HMO was adjusted for HHAZ and season. Low antitrypsin was adjusted for maternal age, parity, and season. Values with
different superscript letters were significantly different (P , 0.05) in pairwise comparisons. HHAZ, household asset z score; HMO, human milk oligosaccharide; IFA, iron and folic
acid; LNS, lipid-based nutrient supplement; MMN, multiple micronutrient.
2 P values are presented for the interaction of group 3 effect modifier on the outcome variable.
3 Global P values are presented for the 3-group comparison.
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women with higher BMI (36), and the higher dose of iron in the
IFA group than in the MMN and LNS groups may have been
sufficient to maintain higher amounts of breast milk IgA. We
could find no studies on the association between maternal iron
status and breast milk IgA, although IgA has been shown to be
significantly lower in the colostrum of anemic women than in
nonanemic women (37). Among young primiparous women,
those in the IFA group had lower odds of low antitrypsin than
did those in the LNS group, whereas there were no group
differences among older or multiparous women. It is plausible
that the higher dose of iron consumed during pregnancy by
young primiparous women in the IFA group positively influ-
enced the production of antitrypsin, although we could find no
evidence in the literature that iron status affects milk antitrypsin.
The strengths of this study include the large sample size,
frequent follow-up with participants throughout the intervention
period, and well-trained study staff. With regard to limitations,
those included in this analysis were of lower socioeconomic status
and had lower BMI values than those excluded from the study,
which may limit the generalizability of the findings to the greater
population. Although the differences between included and
excluded participants were significant, they were quite small.
Another potential limitation is that multiple outcomes were
examined, so the significant finding for low osteopontin could be
attributable to chance.
In conclusion, this study does not support the hypothesis
that providing LNSs or MMNs during pregnancy and #6 mo
postpartum impacts mean concentrations of HMOs or par-
ticular bioactive proteins among lactating women at 6 mo
postpartum in rural Malawi. Other factors (including genet-
ics) may be more influential than diet with regard to these
human milk constituents. Further research is needed to
elucidate which maternal factors, if any, can be modified to
enhance the concentration of beneficial HMOs and proteins in
breast milk.
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